| NRC Q1 Earnings Dip Y/Y Amid Rising Interest Costs, Shares Up 13% |
National Research reports a year-over-year decline in Q1 earnings, pressured by rising interest costs, declining revenues, and higher debt levels amid ongoing sales force expansion. |
zacks.com |
2025-05-02 18:15:34 |
Czytaj oryginał (ang.) |
| NRC Health Announces First Quarter Results |
LINCOLN, Neb.--(BUSINESS WIRE)--National Research Corporation, dba NRC Health, (NASDAQ:NRC) today announced results for the first quarter 2025 and other corporate developments. Highlights: Total Recurring Value Contract Value Increases Sequentially Sales Force Expansion Accelerates New Share Repurchase Program Announced Operating Expenses Decline Dividend Declared Overview Michael D. Hays, Chief Executive Officer of NRC Health, commented on the Company's performance and recent developments: “Th. |
businesswire.com |
2025-04-28 21:00:00 |
Czytaj oryginał (ang.) |
| NANO Nuclear and University of Illinois Urbana-Champaign Receive Nuclear Regulatory Commission (NRC) Fuel Qualification Methodology Approval for KRONOS MMR™ Energy System |
Safety Evaluation Issued by NRC Confirms Regulatory Acceptance of Fuel Qualification Methodology, Paving the Way for Eventual KRONOS Microreactor Deployment at University of Illinois Urbana-Champaign |
globenewswire.com |
2025-04-22 17:32:00 |
Czytaj oryginał (ang.) |
| National Research Corporation Declares Quarterly Dividend |
LINCOLN, Neb.--(BUSINESS WIRE)--National Research Corporation, dba NRC Health, (NASDAQ: NRC) announced that its Board of Directors has declared a quarterly cash dividend of $0.12 (twelve cents) per share payable Friday, April 11, 2025, to shareholders of record as of the close of business on Friday, March 28, 2025. For more than 40 years, NRC Health (NASDAQ: NRC) has led the charge to humanize healthcare and support organizations in their understanding of each unique individual. NRC Health's co. |
businesswire.com |
2025-03-24 19:00:00 |
Czytaj oryginał (ang.) |
| Amazon-Owned One Medical CEO Trent Green to Move to NRC Health |
The CEO of Amazon-owned One Medical, Trent Green, will leave that position to become CEO of National Research Corporation, a publicly traded provider of healthcare solutions doing business as NRC Health. NRC Health announced the move in a Wednesday (March 5) press release, saying Green will join the company June 1. |
pymnts.com |
2025-03-05 17:42:16 |
Czytaj oryginał (ang.) |
| UofL Health Chooses NRC Health to Elevate Patient and Employee Experience Initiatives |
LOUISVILLE, Ky.--(BUSINESS WIRE)-- #EmployeeExperience--UofL Health selects NRC Health to elevate patient and employee experience across its health system. |
businesswire.com |
2025-02-25 10:03:00 |
Czytaj oryginał (ang.) |
| NRC Health ranked #1 Best in KLAS for Healthcare Experience Management |
LINCOLN, Neb.--(BUSINESS WIRE)-- #BIK--NRC Health, a leader in advanced technology and data-driven insights to deliver Human Understanding across the healthcare ecosystem, has proudly announced its recognition as the recipient of the esteemed 2025 Best in KLAS Award for Healthcare Experience Management for the second time in three years. This award once again underscores NRC Health's relentless pursuit of excellence in healthcare experience management through innovation and deep partnerships, in which. |
businesswire.com |
2025-02-05 10:01:00 |
Czytaj oryginał (ang.) |
| National Research's Q4 Earnings Drop Y/Y, Stock Falls 9% |
NRC's Q4 EPS drops to 28 cents despite revenue growth, hit by rising costs and higher interest expenses. |
zacks.com |
2025-01-30 14:36:32 |
Czytaj oryginał (ang.) |
| National Research Corporation Announces Fourth Quarter Results |
LINCOLN, Neb.--(BUSINESS WIRE)--National Research Corporation, dba NRC Health, (NASDAQ:NRC) today announced results for the fourth quarter 2024 and other corporate developments. Financial Results Revenue for the quarter was approximately $36.9 million compared with approximately $38.0 million in the 2023 quarter. Earnings per diluted share were $0.28 compared with $0.36 for the 2023 quarter. At December 31, 2024, the Company's net indebtedness (total borrowing minus cash and cash equivalents) w. |
businesswire.com |
2025-01-27 19:00:00 |
Czytaj oryginał (ang.) |
| BTQ Technologies Announces Funding from National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) |
Funding: BTQ Technologies will receive funding of up to $150,000 from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP). This funding will enhance BTQ's IP portfolio, contributing to the company's R&D efforts. |
prnewswire.com |
2024-12-23 09:30:00 |
Czytaj oryginał (ang.) |
| Zacks Initiates Coverage of NRC Health With Neutral Recommendation |
Discover why Zacks has given NRC Health a "Neutral" rating, being the first on Wall Street to initiate coverage on the stock. Dive into the company's AI innovations, strategic partnerships, and financial resilience, along with the challenges of revenue declines, rising debt and stiff competition. |
zacks.com |
2024-11-27 15:41:10 |
Czytaj oryginał (ang.) |
| Signature Healthcare Elevates Patient Experience and Workforce Engagement Through Strategic Partnership With NRC Health |
LINCOLN, Neb.--(BUSINESS WIRE)-- #HealthcareInnovation--Signature Healthcare has selected NRC Health to enhance its network through human-centered healthcare solutions and data-driven insights. |
businesswire.com |
2024-11-20 11:02:00 |
Czytaj oryginał (ang.) |
| National Research Corporation Announces Third Quarter Results |
LINCOLN, Neb.--(BUSINESS WIRE)--National Research Corporation, dba NRC Health, (NASDAQ:NRC) today announced results for the third quarter 2024 and other corporate developments. Financial Results Revenue for the quarter was approximately $35.8 million compared with approximately $37.9 million in the 2023 quarter. Earnings per diluted share were $0.24 compared with $0.32 for the 2023 quarter. At September 30, 2024, the Company's net indebtedness (total borrowing minus cash and cash equivalents) w. |
businesswire.com |
2024-10-25 21:00:00 |
Czytaj oryginał (ang.) |
| National Research Corporation Announces Second Quarter Results |
LINCOLN, Neb.--(BUSINESS WIRE)--National Research Corporation, dba NRC Health, (NASDAQ:NRC) today announced results for the second quarter 2024 and several other corporate developments. Financial Results Revenue for the quarter was approximately $35 million compared with approximately $36 million in the 2023 quarter. Earnings per diluted share were $0.26 compared with $0.29 for the 2023 quarter. At June 30, 2024, the Company's net indebtedness (total borrowing minus cash and cash equivalents) w. |
businesswire.com |
2024-08-06 21:00:00 |
Czytaj oryginał (ang.) |
| NANO Nuclear Energy Appoints Distinguished Nuclear Regulatory Expert David Tiktinsky as Head of Nuclear Regulatory Licensing after nearly 40-years with the Nuclear Regulatory Commission (NRC) |
Tiktinsky's nearly 40 years of experience at the U.S. Nuclear Regulatory Commission to greatly assist NANO Nuclear in navigating the complex U.S. nuclear licensing process |
globenewswire.com |
2024-07-22 12:30:00 |
Czytaj oryginał (ang.) |
| Top 5 Health Care Stocks That May Explode In July |
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. |
benzinga.com |
2024-07-08 12:40:10 |
Czytaj oryginał (ang.) |
| ASML's secret sauce for semiconductor success amid challenges in the Angstrom Era |
TAIPEI, May 20, 2024 /PRNewswire/ -- Moore's Law is not advancing as fast as it used to be under 2nm and even into the Angstrom level, and competitors are trying to catch up. Can ASML, the Dutch semiconductor equipment maker, continue its monopolistic leadership in the extreme ultraviolet (EUV) lithography equipment market? Will the world's most advanced high-NA EUV machines be the ultimate weapon for a technological leapfrog for its customers? And how would the geopolitical uncertainties change ASML's strategy in the future? G. Dan Hutcheson, vice chair of TechInsights, who has covered ASML since the 1970s, when it was still a subsidiary of Philips, and Marc Hijink, the author of Focus – the ASML Way and a reporter at Dutch newspaper NRC, joined DIGITIMES Asia for an insightful talk to address these questions. Navigating geopolitical uncertainties Although ASML and other semiconductor equipment providers benefit from the demand driven by export controls imposed by the United States to China, geopolitics may have long-lasting implications on the industry as extra capacities and ecosystems are built. Hutcheson and Hijink see ASML following their customers' footsteps to decentralize their productions from the Western Pacific corridor to the United States and Europe. Still, the efficiency of its customers' fab operations may be a concern. "We're in a new world where the utilization of the tools is lower," said Hutcheson, "The problem is, if you can't find the workers to run the tools or to repair them, keep them running, your wafer fab is useless." Hijink observed that Asia will remain an important center for chip production in the future despite the onshoring efforts of various countries and the talent shortage issue since South Korea and Taiwan remain an important part of ASML's expansion. ASML's monopoly status unlikely to be challenged Yet, Hijink cautioned, "ASML's biggest fear is that the current restrictions on Chinese technology might even stimulate it in the long term and create an even bigger problem." He pointed out that the less China gets access to these Western lithography tools, the more the Chinese companies are inclined to build their own. "Even though they might not be able to compete with ASML and Nikon now, you see more room for growth and R&D money in the long term." Yet, Hutcheson believes no company can challenge ASML lithography monopoly without massive government subsidies. "Five decades ago, I developed this maxim that the number of unsubsidized competitors a market can sustain is equal to 1/5 the total market size divided by the cost to develop a new generation of technology, and then you subtract 1.5 times that cost," said Hutcheson. "To attract another competitor in the market, the risk bar must be low enough that there's enough available R&D to support the development of at least 1.5 more tools than what exists in the market at that time." Over those five decades, that maximum is held across 100, or there have been more sub-markets of semiconductor equipment, and that explains the market consolidation of the market from more than 20 semiconductor equipment makers in the 1980s to just a handful right now for lithography, explained Hutcheson. As a semiconductor industry veteran, Hutcheson witnessed how ASML survived over the past four decades of vicissitudes through better management and technological development. Hijink added that ASML survived because it out-invested in R&D during the low cycles despite being on the brink of bankruptcy several times and cleverly invited its customers TSMC, Intel, and Samsung to invest in it and co-develop the EUV machine. By getting the investments, ASML managed to get the money to acquire Cymer, the light source company based in San Diego, and establish a strategic alliance with Zeiss, the German lens maker. Those key components and e-beam technology created ASML's secret sauce of success that competitors cannot copy. However, repeating such success is getting harder. "No single company can afford to do it alone, as R&D becomes more and more expensive," Hutcheson quoted John Chen of Nvidia, who was the first R&D president at TSMC, that," IC no longer means integrated circuit going forward, IC means industry collaboration." Hutcheson estimates that the cost of developing a new EUV tool from scratch would require multiple trillions of dollars, which is equal to the Gross Domestic Product for some countries, and that's assuming that one gets around all the IP barriers in place. "To some extent, it levels the geopolitical playing field. So maybe EUV should receive the Nobel Peace Prize because no country can attack any other country unless they have the EUV," quipped Hutcheson. Can high-NA machines help technology leapfrog? As Intel, Samsung, and TSMC are aiming to mass produce 2nm chips in the next few years and advance towards 1.4-1.6 nm, the ASML's high-NA EUVs are making the headlines of semiconductor industry newspapers. As always, ASML ships the US$300 million High-NA machines to customers according to the timetable agreed with customers and does the laborious adjusting and error corrections with customers. The media has been describing high-NA EUVs as the key for technology catch-uppers to leapfrog the incumbent. However, Hutcheson delved deeply into the intricacies involved in the complex processes of semiconductor manufacturing beyond lithography. "There's a lot of technology issues in the 2nm and 1.4nm era. And we will have to see if they can pull it off and turn it into an advantage," Hutcheson explained that lithography is not the only factor at stake, there are also issues with the gate-all-around (GAA) structures, due to the leakage problems with that. "There's also reliability problems, and the epitaxial layer is pretty poor. So really, there are more material and systems engineering problems than lithography problems." Though Intel has seemingly bought up all available high-NA machines for the year, TSMC is not in a hurry to apply it to its 1.4-1.6nm process. However, ASML said all of their customers who have bought EUVs are going to upgrade to High-NA EUVs. "I think that Intel has to do more, try to leapfrog TSMC, which is a daring move, but that's just one part of Intel's challenge," said Hijink. "Their biggest challenge is not the technology, but the fact that they want to do foundry business because they have to create enough wafer footprint or enough scale to be economically viable with huge competitors like Samsung and TSMC. So that adds to the problem of adopting a new technology where they're not as experienced." Hutcheson cautioned that it is too early to judge the outcome of technology competitions. Yet seeing from the history of the semiconductors industry, decades of research, blood, sweat, and tears, and fixing tons of errors, plus making the right decisions at the right timing and building deep trust with customers made ASML and TSMC what they are today. ASML, a blend of European, Asian, and American cultures as the result of acquisitions, can be a great teacher for TSMC, which is just starting to expand its footprints to the US and Europe. With such a close bond between the two, with AI being the main driving force for semiconductor's future growth, one can be sure there will not be short of fascinating stories in the future. Editor's note: For more insights and analysis from Hutcheson and Hijink on the industry, watch DIGITIMES Asia's new GeoWatch video, 'Decoding Excellence: ASML's Evolution Towards Leadership and Beyond.' Click the link here to access this informative video: https://dgt.ms/geowatch0516 |
https://www.prnewswire.com |
2024-05-20 07:02:00 |
Czytaj oryginał (ang.) |
| National Research Corporation (NRC) Q1 2024 Earnings Call Transcript |
National Research Corporation [NRC] Q1 2024 Earnings Conference Call May 8, 2024 11:00 AM ET Company Participants Linda Stacy - VP, Finance Mark Scudder - ELT Helen Hrdy - CCO Operator Good morning or good afternoon all, and welcome to the National Research Corporation First quarter earnings call. My name is Adam, and I'll be your operator today. |
seekingalpha.com |
2024-05-11 13:43:08 |
Czytaj oryginał (ang.) |
| National Research Corporation Announces First Quarter Results |
LINCOLN, Neb.--(BUSINESS WIRE)--National Research Corporation, dba NRC Health, (NASDAQ:NRC) today announced results for the first quarter 2024. CEO Commentary Michael Hays, Chief Executive Officer, commented: “NRC continues to be strongly positioned for growth in our expanding markets. Our decades of benchmarks and trusted thought leadership afford healthcare insights unavailable to most competitors, while our client service remains unmatched, and we continue to roll out innovative new products. |
businesswire.com |
2024-05-07 21:00:00 |
Czytaj oryginał (ang.) |
| National Research Corporation to Broadcast Its First Quarter 2024 Conference Call Live on the Internet |
LINCOLN, Neb.--(BUSINESS WIRE)--National Research Corporation (NASDAQ:NRC) today announced that it will provide an online web simulcast of its 2024 first quarter earnings conference call on Wednesday, May 8, 2024. The Company's results for the 2024 first quarter will be released after the close of the market on Tuesday, May 7, 2024. The live broadcast of National Research Corporation's conference call will begin at 11:00 a.m. Eastern Time on May 8, 2024. A 30-day online replay will be available. |
businesswire.com |
2024-04-18 20:23:00 |
Czytaj oryginał (ang.) |
| Veteran Patient Experience Executive Jennifer Baron Joins NRC Health as Its First Chief Experience Officer |
LINCOLN, Neb.--(BUSINESS WIRE)-- #HealthcareInnovation--NRC Health, a recognized leader providing solutions and data driven insights for improving health care experiences, announced today the appointment of Jennifer Baron as the organization's first chief experience officer. Baron's addition is part of the organization's continued investments in leadership and innovation to align with the evolving healthcare landscape. In this newly created role, Baron will lead NRC Health's experience strategy, sustaining and advanci. |
businesswire.com |
2024-04-02 15:55:00 |
Czytaj oryginał (ang.) |
| National Research Corporation (NRC) Q4 2023 Earnings Call Transcript |
National Research Corporation (NRC) Q4 2023 Earnings Call Transcript |
seekingalpha.com |
2024-02-14 15:55:06 |
Czytaj oryginał (ang.) |
| National Research Corporation Announces Fourth Quarter and Calendar Year 2023 Results |
LINCOLN, Neb.--(BUSINESS WIRE)--National Research Corporation, dba NRC Health, (NASDAQ:NRC) today announced results for the fourth quarter 2023. CEO Commentary Michael Hays, Chief Executive Officer, commented: “We're pleased to start 2024 with momentum from another consecutive quarter of growth in new sales and operating margin. We have trimmed non-core service lines, and developed our capability across the patient, customer, and employee experience continuum to focus on our clients' most impor. |
businesswire.com |
2024-02-13 19:00:00 |
Czytaj oryginał (ang.) |
| National Research Corporation to Broadcast Its Fourth Quarter and Year-end 2023 Conference Call Live on the Internet |
LINCOLN, Neb.--(BUSINESS WIRE)--National Research Corporation (NASDAQ:NRC) today announced that it will provide an online web simulcast of its 2023 fourth quarter and year-end earnings conference call on Wednesday, February 14, 2024. The Company's results for the 2023 fourth quarter will be released after the close of the market on Tuesday, February 13, 2024. The live broadcast of National Research Corporation's conference call will begin at 11:00 a.m. Eastern Time on February 14, 2024. A 30-da. |
businesswire.com |
2024-02-01 17:00:00 |
Czytaj oryginał (ang.) |
| National Research Corporation Elevates Leadership Team to Seize Growth Opportunity |
LINCOLN, Neb.--(BUSINESS WIRE)--National Research Corporation, dba NRC Health, (NASDAQ:NRC) has announced the following appointments of four newly created executive officer positions: Helen Hrdy – Chief Customer Officer Jason Hahn – Chief Revenue Officer Christophe Louvion – Chief Product Technology Officer Andy Monnich – Chief Corporate Development Officer Helen Hrdy, a leader at NRC Health, has been promoted to the role of Chief Customer Officer significantly expanding her responsibilities. J. |
businesswire.com |
2024-01-17 17:00:00 |
Czytaj oryginał (ang.) |
| National Research Corporation Declares Quarterly Dividend |
Lincoln, Nebraska, Nov. 17, 2023 (GLOBE NEWSWIRE) -- National Research Corporation, dba NRC Health, (NASDAQ:NRC) announced that its Board of Directors has declared a quarterly cash dividend of $0.12 (twelve cents) per share payable Friday, January 12, 2024, to shareholders of record as of the close of business on Friday, December 29, 2023. |
globenewswire.com |
2023-11-17 19:00:00 |
Czytaj oryginał (ang.) |
| Lilly Announces the Receipt of NRC Consent in Connection with its Proposed Acquisition of POINT Biopharma |
INDIANAPOLIS , Nov. 14, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Nuclear Regulatory Commission ("NRC") has issued its consent for the indirect transfer of control of POINT Biopharma Global Inc.'s (NASDAQ: PNT) radioactive materials license (the "NRC Consent"), which will occur following the completion of Lilly's previously announced tender offer to acquire all of the issued and outstanding shares ("Shares") of common stock of POINT, for a purchase price of $12.50 per share in cash, without interest and less any applicable tax withholding. Obtaining the NRC Consent is the last regulatory approval necessary for the consummation of the transaction. |
prnewswire.com |
2023-11-14 18:33:00 |
Czytaj oryginał (ang.) |
| National Research Corporation (NRC) Q3 2023 Earnings Call Transcript |
National Research Corporation (NASDAQ:NRC ) Q3 2023 Results Conference Call November 8, 2023 11:00 AM ET Company Participants Kevin Karas - CFO Linda Stacy - VP, Finance Conference Call Participants Operator Hello, everyone, and welcome to the National Research Corporation Third Quarter 2023 Earnings Call. My name is Charlie and I'll be coordinating the call today. |
seekingalpha.com |
2023-11-08 17:11:03 |
Czytaj oryginał (ang.) |
| National Research Corporation Announces Third Quarter 2023 Results |
LINCOLN, Neb., Nov. 07, 2023 (GLOBE NEWSWIRE) -- National Research Corporation, dba NRC Health, (NASDAQ:NRC) today announced results for the third quarter 2023. |
globenewswire.com |
2023-11-07 19:00:00 |
Czytaj oryginał (ang.) |